The quest to find new lead compounds with anti-diabetic effects via the inhibition of α-glucosidase and α-amylase had led us to conduct bioassay guided isolation of three African medicinal plants which resulted in the identification of bicyclo[2.2.0]hexane-2,3,5-triol (1), 3β-O-acetyl betulinic acid (2) and 2,7-dihydroxy-4H-1-benzopyran-4-one (3), as the bioactive compounds. The compounds demonstrated a significant (P < 0.05) inhibitory effect on α-glucosidase and α-amylase activities than acarbose. Steady state kinetic analysis revealed that compounds 1 and 2 inhibited both α-amylase and α-glucosidase in noncompetitive patterns whilst compound 3 was an uncompetitive inhibitor of α-glucosidase and a non-competitive inhibitor of α-amylase. In conclusion, the study has identified three new active α-glucosidase and α-amylase inhibitory compounds that could have the potential to retard postprandial hyperglycemia.
The incidence of type 2 diabetes (T2D), which is one of the most serious chronic diseases in the world, is increasing because of increased obesity and aging in the general population [1] . The control of postprandial hyperglycemia is considered an effective therapeutic strategy for the treatment of T2D and its associated complications. One of the therapeutic approaches to this control is to retard the digestion and absorption of carbohydrates by inhibiting carbohydrate-hydrolyzing enzymes, such as α-amylase and α-glucosidase, in the digestive organs [2a] . Salivary and pancreatic α-amylases are known to hydrolyze starch and other complex polysaccharides to oligosaccharides and these products of hydrolysis are transported down to the intestinal epithelium. α-Glucosidase is located at the epithelium of the small intestine and specifically hydrolyses oligosaccharides to release α-glucose from the non-reducing end of the sugar [2b] . Hence, effective inhibition of α-amylase and α-glucosidase would significantly delay carbohydrates digestion and glucose absorption, which consequently suppress postprandial hyperglycemia [2c] . Unfortunately, the leading α-glucosidase inhibitors, acarbose and miglitol, are often reported to produce diarrhea and other intestinal disturbances, with bloating, flatulence, cramping and abdominal pain occurring concurrently [3a] . Thus, efforts are targeted for drug discovery from natural products since they serve as a major source of new molecular entities [3b] due to their low cost, relative safety, likelihood of high compliance and low incidence of major undesirable side effects [4] . In this context, African medicinal plants may provide the much needed new chemical leads for the development of novel α-glucosidase inhibitors [5] . Therefore, our current focus is to conduct a thorough bioassay-directed isolation using α-amylase and α-glucosidase as a guide to identify the bioactive compounds in African medicinal plants.
In a previous study, we subjected various extracts and solvent fractions from different parts of Khaya senegalensis A. Juss (Meliaceae) to in vitro α-amylase and α-glucosidase inhibitory assays and observed that the most potent fraction was the butanol fraction derived from the root part of the plant [6] . Interestingly, this butanol fraction of K. senegalensis root (KSBF) further demonstrated potent anti-diabetic activity in a T2D model of rat [7] . In other studies, the acetone fraction of Cassia singueana Delile (Caesalpiniaceae) stem bark (CSAF) was found to possess the highest α-amylase and α-glucosidase inhibitory activity among various solvent fractions from different parts of the plant [8] whilst the butanol fraction of Ziziphus mucronata root (ZMBF) had the best α-amylase and α-glucosidase inhibitory activity among various solvent fractions from the plant. In the present study, we subjected the KSBF, CSAF and ZMBF to detailed bioassay-guided isolation to identify and characterize the bioactive α-amylase and α-glucosidase inhibitory compounds from each of the fractions.
The isolated compound from KSBF was identified as bicyclo[2.2.0]hexane-2,3,5-triol (1) (Figure 1 ) through detailed spectral analysis. Studies of α-glucosidase and α-amylase inhibitory activity of the bicyclo[2.2.0]hexane-2,3,5-triol revealed that the compound is a potent inhibitor of α-glucosidase and α-amylase activity with IC 50 values of 45.9 ± 6.5 and 63.3 ± 10.1 µg/mL respectively. Furthermore, enzyme kinetics studies revealed that the compound exerts a non-competitive inhibition pattern on both enzymes thereby decreasing the V max of the enzymes while the K M remained unchanged (Figure 2 ). For α-glucosidase, the V max was reduced from 655.09 μmol/min to 66.52 μmol/min and the K M remained unchanged at 2 mM while for α-amylase, the V max was reduced from 33.70 μmol/min to 0.86 μmol/min and the K M remained unchanged at 0.25%. The structure of the active compound obtained from CSAF was determined as 3β-O-acetyl betulinic acid (2) (Figure 1 ) [9] . The compound inhibited α-glucosidase and α-amylase activity with IC 50 values of 45.1 ± 3.5 and 98.5 ± 2.8 µg/mL respectively. Furthermore, enzyme kinetics studies revealed that 3β-O-acetyl betulinic acid exerts a non-competitive inhibition pattern on both enzymes thereby decreasing the V max of the enzymes while the K M remained unchanged (Figure 3) .
NPC Natural Product Communications

The
1 H NMR spectrum of the bioactive fraction obtained from ZMBF indicated that it contained a mixture of an aromatic compound (3) and polar aliphatic chains. While it was not possible to identify the aliphatic chains, it was possible to elucidate a structure for the chromone based on its NMR data. With regard to the aliphatic chains, it was also difficult to ascertain the number of chains that co-eluted with the chromone. However, the NMR data of compound 3 showed a characteristic NMR pattern for an A ring chromone system [13] but the data were not consistent with Lai et al. [10] for 3,7-dihydroxy-4H-1-benzopyran-4-one, which would result if the hydroxy group was placed at C-3. Compound 3 was thus identified as 2,7-dihydroxy-4H-1-benzopyran-4-one ( Figure 1 ) after extensive analysis of the spectroscopic data. This chromone (3) can tautomerise between 2,7-dihydroxychromone (3) and 4,7-dihydroxycoumarin [11] , but compound 3 is stabilized by hydroxy substitution at C-7. The enzyme inhibitory studies revealed that the compound inhibited -glucosidase and -amylase catalyzed reactions with IC 50 values of 39.0 ± 4.2 and 93.7 ± 5.4 µg/ml respectively. Using a kinetics approach, the compound was found to be an uncompetitive inhibitor of -glucosidase thereby decreasing both the V max and K M of the enzyme. The V max decreased from 655.09 μmol/min to 48.16 μmol/min while the K M decreased from 2 mM to 0.9 mM (Fig. 4A ). On the other hand, compound 3 inhibited -amylase in a non-competitive fashion with V max decreasing from 33.70 μmol/min to 1.53 μmol/min while the K M remained unchanged at 0.25% ( Figure 4B ).
The role of medicinal plants in modern drug discovery has been duly recognized [12] . In fact, 75% of the anti-infectious agents and 60% of the anticancer drugs approved from 1981-2002, are originally derived from natural sources [13a] whereas 61% of all new chemical compounds marketed as drugs worldwide during the same period are also derived from natural products [13b] . In the present study, we reported the isolation of bioactive chemical compounds from 3 African medicinal plants that might have the potential to delay postprandial hyperglycemic excursions.
Bioassay guided isolation for the potential bioactive anti-diabetic agent in the KSBF led to the isolation of bicyclo[2.2.0]hexane-2,3,5-triol. This is the first time the compound was isolated from any part of K. senegalensis. Indeed, apart from a report on the isolation of dimeric proanthocyanidins [14] from the stem bark of the plant, all other studies on the phytochemistry of this plant reported mainly on limonoids [15] [16] [17] . Interestingly, the compound was found to be a potent inhibitor of the two enzymes (-glucosidase and -amylase) in in vitro models suggesting that the compound could lead to a reduction in postprandial hyperglycemic shoot up. Furthermore, kinetic delineation of α-glucosidase and -amylase inhibitions indicated non-competitive patterns for both enzymes. The observed non-competitive binding of bicyclo [2.2.0]hexane-2,3,5-triol to the two enzymes could be linked to the hydroxyl groups located at C-2, C-3 and C-5 of the compound. The α-glucosidase inhibitory effects of many compounds have been linked to hydroxyl groups [2a,4] . Indeed, the α-amylase inhibitory activities of some phenolics were proposed to occur through the formation of hydrogen bonds between the hydroxyl groups of the Detailed phytochemical analysis of the ZMBF led to the isolation of a chromone, 2,7-dihydroxy-4H-1-benzopyran-4-one. Apart from few reports on cyclopeptide alkaloids isolated from this plant [19a,b] , not much information on the isolation and characterization of other phytochemical compounds from this plant have been reported in the literature. Interestingly, the chromone isolated in this study was found to be a dual inhibitor of the two enzymes (-glucosidase and -amylase) in an in vitro model which suggests that this compound could lead to delayed carbohydrate digestion and glucose absorption with concomitant reduction in postprandial hyperglycemic shoot up [19c] . In previous studies, hydroxyl groups have been implicated as the vital structural features responsible for the inhibitory effects of most phytochemicals on α-glucosidase and -amylase proteins [18a,20] . In our study, kinetic delineation of α-glucosidase and -amylase inhibitions by 2,7-dihydroxy-4H-1-benzopyran-4-one revealed uncompetitive and non-competitive patterns respectively. These observations could suggest that one or more hydroxyl groups of the chromones interact individually or synergistically with the enzyme-substrate complexes to inhibit the α-glucosidase and -amylase.
On a general note, the observed higher α-glucosidase inhibitory activity of the compounds over the corresponding α-amylase activity would be of great pharmaceutical interest. This is because some of the side effects associated with the currently available drugs for the management of diabetes are linked with the excessive inhibition of α-amylase activity [21] . Hence, based on the data, the compounds could be ideal anti-hyperglycemic compound(s) or drugs because better clinical outcomes are usually observed when chemical compounds showed mild inhibitory activity against the α-amylase and strongly inhibiting α-glucosidase [21] .
Experimental
Plant materials: The root samples of K. senegalensis and Z. mucronata and the stem bark sample of C. singueana were collected in January, 2011 from the Botanical garden of the Department of Biological Sciences, Ahmadu Bello University Zaria, Nigeria. The plant samples were authenticated at the herbarium unit of the same department and the herbarium voucher specimens were deposited and assigned the repository numbers 900081 (K. senegalensis), 154 (Z. mucronata) and 6863 (C. singueana). The plant materials were immediately washed and shade-dried for about 2-4 weeks to attain constant weights. The dried samples were pounded to fine powder, and then stored individually in air-tight containers for transport to the University of KwaZulu-Natal, South Africa for subsequent analysis.
Extraction, fractionation and bioassay guided isolation of bioactive compounds: Three kilograms (3 kg) of the fine powdered samples were defatted with hexane. For root samples of K. senegalensis and Z. mucronata, the defatted material was extracted with 10 L of ethanol while 10 L of ethyl acetate was used for the extraction of C. singueana stem bark. All samples were soaked in the respective solvent for 48 h and filtered through Whatman filter paper (No 1). The resultant extracts were evaporated under vacuum using a rotary evaporator (Buchi Rotavapor II, Buchi, Germany) at 40 o C to obtain the respective crude ethanol (EtOH) and ethyl acetate (EtOAc) extracts. The yields were 2.91, 1.16 and 4.04% for K. senegalensis, Z. mucronata and C. singueana extracts respectively. For the EtOH crude extracts, 10 g of the sample was dissolved in 200 mL of distilled water:methanol (9:1) and successively partitioned with hexane (2 x 200 mL), dichloromethane (2 x 200 mL), ethyl acetate (2 x 200 mL) and nbutanol (2 x 200 mL). For the EtOAc extract, only hexane, dichloromethane and acetone (each 2 x 200 mL) were used. The fractions were evaporated to dryness under vacuum at 40 o C under reduced pressure. The butanol fractions of K. senegalensis (KSBF) and Z. mucronata (ZMBF) and the acetone fraction of C. singueana (CSAF) displayed the highest in vitro α-glucosidase inhibitory effect (data not shown) amongst the fractions and therefore, were subjected to column chromatography on a silica column (100 mesh).
The KSBF was eluted with ethyl acetate: methanol (8:2, 7:3, 6:4 and 1:1) as the mobile phase to obtain forty fractions of 20 mL each. Fractions were monitored by thin layer chromatography (TLC) and fractions with similar TLC profiles were combined and tested for α-glucosidase inhibitory activity. The combined fraction 10-14 displayed the highest α-glucosidase inhibitory activity and was further subjected to silica gel column chromatography using methanol in dichloromethane (2%-10%) as the mobile phase. Thirty five fractions (I-XXXV) of 15 mL each were collected and fraction XIV was found to be a pure α-glucosidase inhibitory compound which was characterized to be bicyclo[2.2.0]hexane-2,3,5-triol (1).
The CSAF was eluted with hexane:ethyl acetate (8:2, 7:3 and 1:1) as the mobile phase to obtain fifteen fractions (I-XV). Similar fractions were combined according to their TLC profiles. Combined fractions XI-XIII displayed the highest α-glucosidase inhibitory activity and was further fractionated using methanol in dichloromethane (0%-10%) as the mobile phase. Sixty fractions of 15 mL were collected. Fraction 34 was found to be the pure α-glucosidase and α-amylase inhibitory compound and was characterized by NMR to be 3β-O-acetyl betulinic acid (2).
For ZMBF, the elution solvent used was dichloromethane with an increasing gradient of methanol as the solvent system to give fifty seven fractions of 15 mL each. Fractions were monitored by TLC and fractions with similar TLC profiles were pooled together and tested for α-glucosidase inhibitory activity. However, fraction 29 was found to have the best α-glucosidase inhibitory activity but it was a mixture of a chromone and polar aliphatic alcohol, which coeluted in the same fraction and was unable to be separated despite several attempts. The chromone was identified as 2,7-dihydroxy-4H-1-benzopyran-4-one (3).
α-Glucosidase inhibitory activity of the isolated compounds:
The α-glucosidase inhibitory activity of isolated compounds was determined according to the method described by Ademiluyi and Oboh [22] with slight modifications. Briefly, 250 µL of the compound or acarbose at different concentrations (30-240 µg/mL) was incubated with 500 µL of 1.0 U/mL α-glucosidase solution in 100 mM phosphate buffer (pH 6.8) at 37 o C for 15 min. Thereafter, 250 µL of para-nitrophenylglucopyranose (pNPG) solution (5 mM) in 100 mM phosphate buffer (pH 6.8) was added and the mixture was further incubated at 37 o C for 20 min. The absorbance of the released p-nitrophenol was measured at 405 nm and the inhibitory activity was expressed as a percentage of a control sample without the inhibitor.
α-Amylase inhibitory activity of the isolated compounds: The α-amylase inhibitory activity of the isolated compounds was determined according to the method described by Shai et al. [23] with slight modifications. A volume of 250 µL of the compound or acarbose at different concentrations (30-240 µg/mL) was incubated with 500 µL of porcine pancreatic amylase (2 U/mL) in 100 mM phosphate buffer (pH 6.8) at 37 o C for 20 min. 250 µL of 1% starch dissolved in 100 mM phosphate buffer (pH 6.8) was then added to the reaction mixture and incubated at 37 °C for 1 h. Exactly, 1 mL of dinitrosalicylic acid colour reagent was then added and boiled for 10 min. The absorbance of the resulting mixture was measured at 540 nm and the inhibitory activity expressed as a percentage of a control sample without the inhibitor. All assays were carried out in triplicate. The inhibitory activities of the compound for the α-glucosidase and α-amylase were calculated by using the following formula: Inhibitory activity % 1 x 100
Where As is the absorbance in the presence of the sample and Ac is the absorbance of the control.
Mechanism of α-glucosidase and α-amylase inhibitions:
The isolated compounds were subjected to kinetic experiments to determine the type of inhibition exerted on α-glucosidase and α-amylase. The experiments were conducted according to the protocols as described above at a constant concentration of the compounds (120 µg/mL) with a variable concentration of substrate. For the α-glucosidase inhibition assay, 0.625-5.000 mM of pNPG was used and 0.125-1.000% starch was used for the α-amylase inhibition assay. The initial rates of reactions were determined from calibration curves constructed using varying concentrations of pnitrophenol and maltose for the α-glucosidase and α-amylase inhibition assays respectively. The initial velocity data obtained was used to construct Lineweaver-Burke's plot to determine the K M (Michaelis constant) and V max (maximum velocity) of the enzymes as well as the type of inhibition for both enzymes.
